Charcot neuro-osteoarthropathy (CNO), often called Charcot foot, is a destructive complication of diabetes-related peripheral neuropathy in which inflammation drives progressive injury to the bones, joints, and soft tissues of the foot and ankle. Despite affecting an estimated 0.1% to 8% of patients with diabetes and neuropathy, Charcot foot is frequently missed at presentation, with consequences that include severe deformity, ulceration, infection, and major lower-extremity amputation. The release of the first International Working Group on the Diabetic Foot (IWGDF) guideline dedicated to active Charcot neuro-osteoarthropathy in 2023 has refocused clinical attention on the importance of early recognition and prompt offloading.
Why Early Recognition Matters
The natural history of Charcot foot is unforgiving when diagnosis is delayed. In a multicentre cohort published in Diabetes Care (Petrova and colleagues, 2024), 66.7% of patients whose Charcot was diagnosed late required surgical treatment, with an average of 2.9 surgeries per affected limb. By contrast, only 14.3% of patients identified and offloaded at the earliest (Stage 0) phase developed complications severe enough to warrant reconstructive surgery. A separate retrospective analysis of patients treated for active Stage 0/1 disease between 2019 and 2022 (Meloni et al., Journal of Clinical Medicine, 2024) similarly reported that early, complete offloading was associated with successful avoidance of major amputation at one year in patients without severe deformity at presentation.
Wukich and colleagues, writing in Diabetes/Metabolism Research and Reviews in 2024, have argued that the field needs a paradigm shift toward treating Charcot foot as a time-critical condition akin to acute coronary syndrome or stroke, in which “time is tissue” and even short delays meaningfully worsen outcomes.
Clinical Features and Examination
Active Charcot neuro-osteoarthropathy should be suspected in any person with diabetes and peripheral neuropathy who develops a unilaterally warm, swollen, and sometimes erythematous foot, with or without a history of minor trauma. Pain may be present but is often disproportionately mild relative to the degree of inflammation, owing to underlying sensory loss. The 2023 IWGDF guideline emphasizes that comparison with the contralateral foot, including measurement of skin temperature, is a cornerstone of clinical assessment. A sustained side-to-side temperature difference greater than approximately 2°C, measured with a handheld infrared thermometer, supports the diagnosis and can also be used to monitor disease activity over time.
Importantly, the IWGDF advises against relying on systemic inflammatory markers such as C-reactive protein, erythrocyte sedimentation rate, white blood cell count, or alkaline phosphatase to confirm or exclude active CNO in patients with intact skin, as these are typically normal or only mildly elevated.
Imaging
Plain radiographs of the foot and ankle, including weight-bearing anteroposterior, lateral, and oblique views, remain the recommended first-line imaging study. However, in early (Stage 0) disease, radiographs are frequently normal even when significant osseous injury is already present. When clinical suspicion remains high and radiographs are unrevealing, magnetic resonance imaging (MRI) is recommended to detect subchondral bone marrow oedema, microfractures, and joint effusions characteristic of early CNO. The CADOM feasibility trial, published in the Journal of Foot and Ankle Research in 2023, has explored serial MRI as a tool to track resolution and potentially shorten immobilization time, though larger trials are required to confirm benefit.
Management Principles
Immediate Offloading
The cornerstone of treatment for active Charcot foot is prompt, complete, and continuous offloading of the affected limb. The 2023 IWGDF guideline recommends initiating knee-high immobilization, ideally with a non-removable total contact cast (TCC), as soon as the diagnosis is suspected, even before confirmatory imaging is completed. Removable knee-high walkers may be used when adherence with a TCC is impractical, although evidence consistently links non-removable devices with faster resolution.
Casting is continued until clinical and imaging evidence of remission is achieved, defined by resolution of the temperature gradient and stabilization of bony architecture. Reported casting durations vary widely, with most series describing several months of immobilization; in one cohort, almost half of patients ultimately transitioned to specialized or off-the-shelf footwear with custom orthoses, approximately one-quarter required long-term bracing, and a similar proportion proceeded to reconstructive surgery.
Adjuncts and Surgery
Pharmacologic adjuncts, including bisphosphonates and calcitonin, have been studied with mixed results, and current guidelines do not endorse their routine use. Surgical reconstruction is reserved for patients with unstable or severely deformed feet, recurrent ulceration over bony prominences, or failed conservative management. Recent narrative reviews, including the evidence-based surgical algorithm published in Frontiers in Clinical Diabetes and Healthcare (2024), highlight that limb salvage rates are highest when surgery is performed by multidisciplinary teams with experience in diabetic foot reconstruction.
Key Clinical Takeaways
Charcot neuro-osteoarthropathy is a clinical diagnosis driven by pattern recognition: a warm, swollen foot in a person with diabetes and neuropathy should be considered active CNO until proven otherwise. Early offloading at Stage 0 is associated with substantially lower rates of deformity, recurrence, and amputation. Imaging should not delay treatment; when radiographs are normal but suspicion is high, MRI is the preferred next step. Temperature monitoring with infrared thermometry provides a simple, evidence-based method for both diagnosis and follow-up. Above all, the recent literature reinforces that outcomes for patients with Charcot foot depend less on which device or surgical technique is used than on how quickly the diagnosis is made and how completely the limb is offloaded.
References
Wukich DK, Raspovic KM, Hobizal KB, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3646.
Raspovic KM, Hobizal KB, Rosenblum BI, et al. Diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus: a systematic review. Diabetes/Metabolism Research and Reviews. 2024;40(3):e3653.
Wukich DK, Schaper NC, Gooday C, et al. Charcot neuroarthropathy in persons with diabetes: it’s time for a paradigm shift in our thinking. Diabetes/Metabolism Research and Reviews. 2024;40(3):e3754.
Petrova NL, Donaldson NK, Bates M, et al. Charcot foot offloading in Stage 0 is associated with shorter total contact cast treatment and lower risk of recurrence and reconstructive surgery: a pilot study. Diabetes Care. 2024;47(2):252-259.
Meloni M, Bellia A, Giurato L, et al. Early treatment of acute Stage 0/1 diabetic Charcot foot can avoid major amputations at one year. Journal of Clinical Medicine. 2024;13(6):1633.
Ramanujam CL, Stapleton JJ, Zgonis T. Charcot neuro-osteoarthropathy: a review of key concepts and an evidence-based surgical management algorithm. Frontiers in Clinical Diabetes and Healthcare. 2024;5:1344359.
Schoots IG, Slim FJ, Busch-Westbroek TE, et al. A randomised feasibility study of serial magnetic resonance imaging to reduce treatment times in Charcot neuroarthropathy in people with diabetes (CADOM). Journal of Foot and Ankle Research. 2023;16:31.
Comments
